By Chloe Elmer
Sometimes, in traveling, the fastest route to a destination requires the traveler to abandon familiar side roads in favor of a newly constructed highway.
In Alzheimer’s disease research, that highway is biomarker-based research. In a special report for the Alzheimer’s Association, Penn Memory Center Co-Director Dr. Jason Karlawish wrote that biomarkers are changing the future of Alzheimer’s disease research.
“In the history of medicine,” Karlawish wrote, “one means to progress is when we make the decision that our assumptions and definitions of disease are no longer consistent with the scientific evidence.”